Dover Corporation Well Positioned for Continued EPS Growth & Stock Price Recovery
<p>Oppenheimer analysts shared their views on <a href='https://financialmodelingprep.com/financial-summary/DOV'>Dover Corporation (NYSE:DOV)</a>, noting that it is well-positioned for continued EPS growth and stock price recovery.</p>
<p>Following a challenging 2022 year for the company’s stock, the analysts believe Dover entered the new year with multiple levers for earnings growth, continued strategic progression, and meaningful share price recovery. </p>
<p>According to the analysts, demand remains positive across the majority of Dover's diversified portfolio and elevated backlog affords a degree of insulation from market uncertainties (including potential re-pricing in more commodity-exposed businesses). Areas of recent portfolio weakness may also transition to catalysts, with biopharma having lapped peak COVID vaccine-related shipments (now awaiting a robust pipeline of biologic therapies) and above-ground fueling in restructuring mode to offset weak demand. </p>
<p>Combined with carryover accretion from 2022 deals (including Witte Pumps), over $500 million in share repurchases, and ample strategic flexibility, the analysts anticipate relative operating and share price outperformance. The analysts maintained their Outperform rating and $164 price target on the company’s stock.</p>

NYSE:DOV